Inhibitor Therapeutics, Inc. (INTI)
OTCMKTS
· Delayed Price · Currency is USD
0.0900
0.00 (0.00%)
At close: Apr 24, 2026
Inhibitor Therapeutics Employees
As of December 31, 2025, Inhibitor Therapeutics had 8 total employees, including 2 full-time and 6 part-time employees. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$660,067
Market Cap
15.53M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Zeo ScientifiX | 20 |
| Oncotelic Therapeutics | 26 |
| HOOKIPA Pharma | 87 |
| Anebulo Pharmaceuticals | 3 |
| Provectus Biopharmaceuticals | 6 |
| Harvard Apparatus Regenerative Technology | 8 |
| Brainstorm Cell Therapeutics | 20 |
Inhibitor Therapeutics News
- 4 weeks ago - Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome - GlobeNewsWire
- 1 year ago - Complement Inhibitor Therapeutics Pipeline Developments Research Report 2024 - GlobeNewsWire
- 1 year ago - Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Complement Inhibitor Therapeutics | DelveInsight - GlobeNewsWire
- 1 year ago - Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan - GlobeNewsWire
- 2 years ago - Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board - PRNewsWire
- 2 years ago - Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University - PRNewsWire